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PD3-1:
MODEL FOR PREDICTING THE RISK OF ISCHEMIC STROKE AFTER
RADICAL PROSTATECTOMY
Teng-Fu Hsieh, Shang-Sen Lee, Chi-Cheng Chen, Hsin-Ho Liu, Tsung-Hsun
Tsai, Tien-Huang Lin. Department of Urology, Taichung Tzu Chi Hospital,
Taichung and School of Medicine, Tzu Chi University, Hualian, Taiwan
Purpose: The aim of this study is to assesses the predictive value of
CHADS2 scores, CHA2DS2-VASc scores and Charlson Comorbidity Index
Score (CCIS) for stroke among patients with prostate cancer.
Materials and Methods: We used Taiwan registry data base, National
Health Insurance Research Database (NHIRD) in this study. We identiﬁed
participants with non- atrial ﬁbrillation (AF) prostate cancer diagnoses
who underwent radical prostatectomy between January 1,1997 and
December 31,2011. CHADS2 scores, CHA2DS2-VASc scores and CCIS were
used to stratify the ischemic stroke risk. The scores were calculated based
on the comorbilities recorded before radical prostatectomy. The receiver
operating characteristics curve (ROC) was used to assess the prediction
accuracy for ischemic stroke. All participants were followed from the date
of enrollment until ischemic stroke, death, or the end of the 5-year follow
up period.
Results: There were5414 patients diagnosed with prostate cancer under-
going radical prostatectomy in this study. The mean age at diagnosis was
65± 6 years. The prediction accuracy for ischemic stroke in better in
CHADS2 scores (AUC¼ 0.971) and CHA2DS2-VASc scores (AUC¼ 0.953)
than CCIS (AUC¼ 0.504).
Conclusions: Our results show that the CHADS2 score could be
applied for ischemic stroke prediction in prostate cancer patients
underwent radical prostatectomy. Cardiovascular risks evaluation and
management are suggested for these patient with higher CHADS2
score.
PD3-2:
DOES IT NEED TO REMOVE PRE-PROSTATIC FAT TO DETECTED LYMPH
NODE METASTASIS OF PROSTATE CANCER DURING ROBOTIC ASSISTED
RADICAL PROSTATECTOMY?
Chia-Hung Chen 1, Hsiao-Jen Chung 1,2,3, Tzu-Ping Lin 1,2,3, Eric YH.
Huang 1,2,3, William JS. Huang 1,2,3, Yen-Hwa Chang 1,2,3, Alex TL.
Lin 1,2,3, Kuang-Kuo Chen 1,2,3. 1Department of Urology, Taipei Veterans
General Hospital, Taipei, Taiwan; 2Department of Urology, School of
Medicine, National Yang-Ming University, Taipei, Taiwan; 3 Shu-Tien
Urological Science Research Center, Taipei, Taiwan
Purpose: To determine the number of lymph node of pre-prostatic fat and
the incidence of metastatic lymph nodes in the lymph node dissection
during robotic assisted radical prostatectomy(RARP)
Materials and Methods: During December 2012 to September 2015, pre-
prostatic fat was removed in182 patients who underwent RARP. These
tissues were sent for pathological analysis to determinate the number of
lymph nodes and the count of metastatic lymph nodes. Another 128 pa-
tients without pre-prostatic fat removal were collected as control group.
Operation features, such as time consumption of operation, estimated
blood loss, day of hospitalization, and incidence of complication were
compared within these two groups.
Results: Lymph nodes within pre-prostatic fat were detected in 17/
188(9%) patients. Metastatic lymph node was found in 2/188 (1%)
among these patients. Patients with metastatic lymph nodes in pre-
prostatic fat had no obturator lymph nodes involved. There were no
signiﬁcant differences of operation features between experimental and
control group.
Conclusions: Our analysis demonstrates that pre-prostatic fat contains
lymph nodes. The rate of present of lymph node metastases was high.
There was no increasing of the risk of surgery for Pre prostatic fat
removal. Therefore, It should be routinely removed and received
pathological analysis at radical prostatectomy for precise lymph node
stagingPD3-3:
PREVENTION AND MANAGEMENT OF COMPLICATIONS DURING
ROBOTIC ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY FROM
COMPREHENSIVE PLANNING : EXPERIENCE OF A SINGLE SURGEON OF
1000 CASES
Yen-Chuan Ou 1,2,6, Chun-Kuang Yang 1,6, Kuangh-Si Chang 2,6, John
Wang 3,6, Siu-Wan Hung 4,6, Min-Che Tung 5,6, Ashutosh K.
Tewari 7, Vipul R. Patel 8. 1Division of Urology, Department of Surgery,
Taichung Veterans General Hospital, Taichung, Taiwan; 2Department of
Research, Taichung Veterans General Hospital, Taichung, Taiwan;
3Department of Pathology, Taichung Veterans General Hospital, Taichung,
Taiwan; 4Department of Radiation, Taichung Veterans General Hospital,
Taichung, Taiwan; 5Division of Urology, Department of Surgery, Tungs’
Taichung MetroHarbor Hospital, Taichung, Taiwan; 6 School of Medicine,
National Yang-Ming University, Taipei, Taiwan; 7Department of Urology,
Icahn School of Medicine at Mount Sinai, New York, NY, USA; 8Global
Robotics Institute, Florida Hospital, Orlando, FL, USA
Purpose: To report how to prevent and manage complications of robotic
assisted laparoscopic radical prostatectomy (RALP) performed by a single
surgeon in Taiwan from 1000 cases experience.
Materials and Methods: Complication (Clavien system) rates were pro-
spectively assessed in 1000 consecutive patients undergoing RALP (Group
I: cases 1-200, IIa: 201-400, IIb: 401-600, IIIa: 601-800 and IIIb:801-1000).
Preoperative evaluation focus on gouty history, drugs inﬂuence clotting
time and cardiopulmonary problems. Magnetic resonance imaging were
routinely done. Operative difﬁculty was assessed including neo-adjuvant
hormonal therapy (NHT), obese patients (BMI>30), prostate volume>70 g,
large median lobe with intravesical protrusion >1 cm, previous tran-
surethral resection of the prostate (TURP), previous pelvic surgery,
received extended pelvic lymph nodes dissection (EPLND), salvage robotic
radical prostatectomy (SRP). Clinical pathway was described below: Pa-
tients were allowed to have water and then resumed regular diet on POD
1-2. The drainage tube was removed and intravenous ﬂuid discontinued
on POD 1-3.
Results: The trend of more older age, higher ASA score, body mass index
(BMI) and more advanced clinical stage from Group I to Group IIIb, it is
signiﬁcantly statistical differences. The trend of cases of NHT, obese pa-
tients (BMI>30), previous pelvic surgery, received EPLND and SRP were
signiﬁcantly increased from Group I to Group IIIb. Conversely, a trendy
signiﬁcantly less blood loss occurred (Group I 179 ml, IIa 117 ml, IIb 90 ml,
IIIa 99ml, IIIb: 97 ml, p<0.001). Blood transfusion (BT) incidence was
gradually reduced from 3.5% to 0.5% in Groups I and IIIb, respectively
(p¼ 0.022). The total complication was 6.4% (64/1000) (surgical/medical :
5% / 1.4%). Statitically signiﬁcant decrease tendency of complication rate
was 12%, 6%, 6%,4% and 4% in Groups I, IIa, IIb, IIIa and IIIb respectively
(p¼ 0.003). The most common complication (11/1000¼1.1%) was blood
transfusion and bowel problem.
Conclusion: Learning curve for every 200 cases of RALP showed signiﬁ-
cantly less complication even the operative difﬁculty was increased. The
keys to prevent complication was preoperation evaluation meticulously,
MRI planning and a dedicated robotic team to do RALP intraoperatively.
Early diagnosis and management of complication is paramount in patients
have any deviation from the normal postoperative course and clinical care
pathway.
PD3-4:
COMPARISONS OF ONCOLOGICAL AND FUNCTIONAL OUTCOMES
AMONG RADICAL RETROPUBIC PROSTATECTOMY, HIGH DOSE RATE
BRACHYTHERAPY, CRYOABLATION AND HIGH-INTENSITY FOCUSED
ULTRASOUND FOR LOCALIZED PROSTATE CANCER: A PROSPECTIVE,
CONTROLLED, NONRANDOMIZED TRIAL
Po-Hui Chiang, Yang Liu-Yi, Po-Yen Chen. Kaohsiung Chang Gung Medical
Center, Department of Urology, Taiwan
Purpose: To conduct a prospective, controlled, nonrandomized, single
institutional comparison for radical retropubic prostatectomy (RRP), high
dose rate brachytherapy (HDRBT), cryoablation and high-intensity focused
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and functional outcomes.
Materials and Methods:We enrolled 97, 161, 114 and 120 patients of RRP,
HDRBT, cryoablation and HIFU respectively for localized prostate cancer
from May 2008 to December 2013. PSA biochemical recurrence, salvage
treatment-free rate, metastasis-free rate, and PSA biochemical recurrence-
free survival were collected for oncological outcomes. Functional out-
comes included complications and serial IIEF-5 scores, IPSS and related
QoL scores.
Results: During nearly three years of follow-up, the patients of HDRBT
experienced higher PSA biochemical recurrence rate overall (54.7%), as
well as D'Amico intermediate-risk (34.4%) and high-risk (61.8%) groups,
lower salvage treatment-free rate (46.7%), andmetastasis-free rate (90.7%).
Besides, the patients of RRP demonstrated higher urethral stricture (29.9%)
and urinary incontinence rate (11.3%). The patients of HIFU revealed lower
de novo erectile dysfunction rate at one year (65.6%), higher serial IIEF-5
scores, lower IPSS and related QoL scores.
Conclusion: Among the four treatments, the patients of HDRBT demon-
strated the worst oncological outcomes in D'Amico intermediate and high-
risk groups. Besides, the patients of RRP had more complications rate in
urethral stricture and urinary incontinence. Moreover, the patients of HIFU
experienced better urinary function improvement and more possible
sexual function preservation. In consideration of trifecta, HIFU may pro-
vide equivalent cancer control and better quality of life for patients of
localized prostate cancer.
PD3-5:
LAPAROSCOPIC RETZIUS-SPARING RADICALPROSTATECTOMY: A
REVERSED EVOLUTION FROM ROBOTIC-ASSISTED RADICAL
PROSTATECTOMY
Kun-Yuan Chiu. Divisions of Urology, Department of Surgery, Taichung
Veterans General Hospital, Taiwan
Purpose: Robot-assisted radical prostatectomy (RaRP) is viewed as the
main surgical option in patients with localized prostate cancer. Robotic-
assisted Retzius-sparing radical prostatectomy (Retzius-sparing RaRP) is
also in development to achieve the trifecta (cancer free, continence and
potency). For economic consideration, we modiﬁed the methodology us-
ing the same Retzius-sparing approach but with laparoscope.
Materials and Methods: A total of 5 patients underwentRetzius-sparing
LRP from May to Augustof 2015. General characters of patients, peri-
operative parameters, functional and oncologic datas were collected. Pa-
tient position and trocar placement is identical with our conventional LRP.
The steps of whole procedurewere very similar to the method that SK Lim,
et al. (BJU Int 2014; 114: 236e244) had published to describe the process of
Retzius-sparing RaRP. Continence was deﬁned as no need for pad in daily
life.
Results: The average operative time was 213 minutesand the average
amount of blood loss was195 ml. Two patients received bilateral NVBpreserving while the other three patients received unilateral partial pre-
serving. Four patients got immediate continence control at the ﬁrst day
after Foley removal. The other one had post-operative anastomotic leakage
and initial mild stress urine incontinence but got recovery in 2 weeks.
Conclusions: At the very ﬁrst time we show the Retzius-sparing LRP is a
feasible option for localized prostate cancer. It might result in early
continence control in our initial experience and with less economic cost-
than RaRPfor patients. Further long-term prospective studies are needed
to deﬁne the beneﬁts of this method.
PD3-6:
THE ASSOCIATION OF INTERLEUKON-10 PROMOTER GENOTYPES TO
TAIWANESE RENAL CELL CARCINOMA SUSCEPTIBILITY
Cheng-Hsi Liao 1,2,3,4, Wen-Shin Chang 2,3, Pei-Shin Hu 6, Hsi-Chin
Wu5, Chia-Wen Tsai 2,3, Chin-Mu Hsu 2,3, Hao-Ai Shui 4, Da-Tian
Bau 1,2. 1Department of Urology, Taichung Armed Forces General Hospital,
Taichung, Taiwan, ROC; 2Graduate Institute of Clinical Medical Science,
China Medical University, Taichung, Taiwan, ROC; 3 Terry Fox Cancer
Research Laboratory, Taiwan, ROC; 4Graduate Institute of Medical Sciences,
National Defense Medical Center, Taipei, Taiwan, ROC; 5Department of
Urology, China Medical University Hospital, Taichung, Taiwan, ROC;
6Department of Ophthalmology, Changhua Christian hospital, Changhua,
Taiwan, ROC
Purpose: Renal cell carcinoma (RCC) accounts for about 3% of all cancer-
related mortalities worldwide and the risk factors for the development of
RCC have not yet been fully elucidated. Mounting proteomic evidence
suggests that inﬂammatory process plays a role in RCC etiology, and
interleukin-10 (IL-10) is an important immunosuppressive cytokine.
However, little is known about the contribution of IL-10 genotypes to RCC.
The study aimed at evaluating the contribution of IL-10 promoter A-1082G
(rs1800896), T-819C (rs3021097), A-592C (rs1800872) genetic poly-
morphisms to the risk of RCC in Taiwan.
Materials and Methods: Associations of the three IL-10 polymorphic ge-
notypes with the risk of RCC were examined among 92 RCC patients and
580 age- and gender-matched cancer-free controls by polymerase chain
reaction-restriction fragment length polymorphism (PCR-RFLP)
methodology.
Results: The pilot results showed that the percentages of TT and TC for IL-
10 T-819C genotypes were signiﬁcantly higher in the RCC patient group
than those in the healthy control group. The CC genotype carriers were of
lower risk for RCC (odds ratio¼ 0.45, 95% conﬁdence interval¼ 0.23-0.72,
p¼ 0.0033). There is no difference in the distribution of A-1082G or A-
592C genotype between the RCC and control groups.
Conclusions: In summary, the CC genotype of IL-10 T-819C genotype may
have a protective effect on RCC risk in Taiwan. Further investigation with
larger sample size in addition to genotype-phenotype correlation and
intracellular mechanisms are our future work.
